BioCentury
ARTICLE | Clinical News

2B3-101: Phase I/IIa started

July 4, 2011 7:00 AM UTC

to-BBB began an open-label, dose-escalation, Dutch Phase I/IIa trial to evaluate 2B3-101 in about 40 patients. The trial includes an extension phase in 10 patients with brain metastases of breast canc...